Crispr Therapeutics AG (CRSP) Receives $46.70 Consensus Price Target from Analysts

Crispr Therapeutics AG (NASDAQ:CRSP) has received a consensus recommendation of “Hold” from the fifteen research firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $46.70.

Several analysts recently weighed in on the company. Zacks Investment Research upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a report on Friday, March 1st. BidaskClub downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 22nd. William Blair assumed coverage on Crispr Therapeutics in a report on Wednesday, March 13th. They issued a “market perform” rating for the company. SunTrust Banks restated a “buy” rating on shares of Crispr Therapeutics in a report on Monday, December 31st. Finally, Needham & Company LLC assumed coverage on Crispr Therapeutics in a report on Sunday, December 9th. They issued a “buy” rating and a $38.72 price objective for the company.

In other Crispr Therapeutics news, President Rodger Novak sold 85,220 shares of Crispr Therapeutics stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $40.40, for a total value of $3,442,888.00. Following the transaction, the president now owns 1,024,534 shares in the company, valued at $41,391,173.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 126,003 shares of company stock worth $4,989,303 in the last quarter. 37.70% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Trexquant Investment LP purchased a new stake in shares of Crispr Therapeutics during the third quarter worth about $250,000. Bank of New York Mellon Corp grew its stake in shares of Crispr Therapeutics by 11.3% during the third quarter. Bank of New York Mellon Corp now owns 34,618 shares of the company’s stock worth $1,535,000 after acquiring an additional 3,514 shares during the last quarter. Shelton Capital Management grew its stake in shares of Crispr Therapeutics by 70.7% during the fourth quarter. Shelton Capital Management now owns 12,800 shares of the company’s stock worth $366,000 after acquiring an additional 5,300 shares during the last quarter. Capital Investment Advisory Services LLC grew its stake in shares of Crispr Therapeutics by 49.6% during the fourth quarter. Capital Investment Advisory Services LLC now owns 25,279 shares of the company’s stock worth $722,000 after acquiring an additional 8,376 shares during the last quarter. Finally, Creative Planning grew its stake in shares of Crispr Therapeutics by 34.9% during the fourth quarter. Creative Planning now owns 14,791 shares of the company’s stock worth $423,000 after acquiring an additional 3,827 shares during the last quarter. Institutional investors own 42.23% of the company’s stock.

NASDAQ:CRSP opened at $35.45 on Friday. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $73.90. The firm has a market cap of $1.85 billion, a PE ratio of -10.31 and a beta of 3.12.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, February 25th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $1.56 million. Crispr Therapeutics had a negative return on equity of 48.35% and a negative net margin of 5,281.08%. The company’s revenue for the quarter was down 99.7% compared to the same quarter last year. On average, equities research analysts predict that Crispr Therapeutics will post -3.33 EPS for the current year.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Featured Story: What is a conference call?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.